Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses

BACKGROUND: The addition of PD-L1 inhibitors to platinum-based chemotherapy (CT) has newly received United States Food and Drug Administration (FDA) approval in extensive stage-small cell lung cancer (ES-SCLC). PD-1 agents similarly improved survival rates, even if not yet supported by international...

Descripción completa

Detalles Bibliográficos
Autores principales: Gristina, Valerio, Galvano, Antonio, Castellana, Luisa, Insalaco, Lavinia, Cusenza, Stefania, Graceffa, Giuseppa, Iacono, Federica, Barraco, Nadia, Castiglia, Marta, Perez, Alessandro, Rizzo, Sergio, Russo, Antonio, Bazan, Viviana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Immunotherapy for Lung Cancer: Progress, Opportunities and Challenges
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504650/
https://www.ncbi.nlm.nih.gov/pubmed/34646363
http://dx.doi.org/10.1177/17588359211018018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504650/
https://www.ncbi.nlm.nih.gov/pubmed/34646363
http://dx.doi.org/10.1177/17588359211018018

Ejemplares similares